Form 4: Nautilus Biotechnology CEO Sujal Patel Granted 650,000 Stock Options

Nautilus Biotechnology's CEO, Sujal M. Patel, was granted 650,000 stock options on March 3, 2025, according to a recent SEC filing.

Summary

• Sujal M. Patel, CEO, President, and Secretary of Nautilus Biotechnology, Inc., was granted 650,000 stock options on March 3, 2025.
• The options have an exercise price of $1.24.
• 25% of the options will vest on the first anniversary of January 1, 2025, and the remainder will vest monthly over the following 36 months, contingent on continued service.
• The options expire on March 3, 2035.
• A Power of Attorney was executed on February 23, 2025, granting Sujal Patel, Matt Murphy, Anna Mowry, Priscilla Chen, Nick Brazell, Zachary Myers and Ben Capps the authority to act on behalf of Sujal Patel in matters related to SEC filings.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The granting of stock options is a standard practice and generally viewed favorably as it aligns management's interests with shareholders. There are no explicitly negative aspects in the filing.

Positives

• The granting of stock options to the CEO aligns his interests with those of the shareholders, incentivizing him to increase the company's value.
• The vesting schedule encourages long-term commitment from the CEO.

Industry Context

Stock option grants are a common practice in the biotechnology industry to attract and retain top executive talent and align their interests with those of shareholders. The size and vesting schedule of the grant are typical for a CEO of a company of Nautilus Biotechnology's size and stage.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotechnology industry.
• Comparable companies such as Pacific Biosciences and Twist Bioscience also utilize stock options as part of their executive compensation strategy.
• The vesting schedule of the options is typical, with vesting occurring over a period of several years to incentivize long-term performance.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the CEO to increase the company's value.
• Employees may see the grant as a sign of confidence in the company's future.

Key Dates